Probenecid
- Generic Name
- Probenecid
- Drug Type
- Small Molecule
- Chemical Formula
- C13H19NO4S
- CAS Number
- 57-66-9
- Unique Ingredient Identifier
- PO572Z7917
- Background
The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
- Indication
For the reduction of serum uric acid concentrations in chronic gouty arthritis and tophaceous gout in patients with frequent disabling gout attacks. Has also been effectively used to promote uric acid excretion in hyperuricemia secondary to the administration of thiazide and related diuretics.
- Associated Conditions
- Bacterial Infections, Chronic Gouty Arthritis, Elevated Serum Uric Acid, Gout Chronic, Hyperuricemia, Infection
FDA Approves Orlynvah for Uncomplicated UTIs with Limited Treatment Options
• The FDA has approved Orlynvah (sulopenem etzadroxil and probenecid) for uncomplicated urinary tract infections (UTIs) in adult women with limited oral antibiotic options.
• Orlynvah combines sulopenem etzadroxil, a broad-spectrum penem antibiotic, with probenecid to enhance sulopenem's effectiveness against resistant bacteria.
• Clinical trials demonstrated Orlynvah's efficacy against _E. coli_, _Klebsiella pneumoniae_, and _Proteus mirabilis_, showing comparable or superior results to traditional antibiotics.
• Common side effects include diarrhea, nausea, yeast infections, and headaches, with the drug contraindicated in patients with specific conditions like gout or blood disorders.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath